CME Presentations

Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Therapies


Presentations


Speakers


CME Information

Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Therapies:
Updates in Diabetic Eye Diseases, Retinal Vein Occlusion and Age-Related Macular Degeneration - A Four-Part Series


Global Logo PQH Logo

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

MODULE ONE: Anti-VEGF Injections in the Era of COVID-19: Implications for Patients
  • Discuss the potential impact of COVID-19 pandemic on the timely delivery of intravitreal anti-VEGF and vision monitoring
  • Review strategies for maintaining optimal therapy for patients needing intravitreal anti-VEGF injections, while reducing COVID-19 transmission to patients, clinicians, and staff
  • Define strategies to prepare patients for clinic visits under COVID-19 policies
MODULE TWO: Management of the Diabetic Retinopathy: What is New?
  • Review how the introduction of anti-VEGF therapy has affected the natural history of DR
  • Highlight limitations of technologies and severity scales currently used to monitor disease progression
  • Review recent clinical trials data and subsequent subanalyses from Diabetic Retinopathy Clinical Research Network (DRCR.net) documenting the impact of anti-VEGF therapy on DR management
MODULE THREE: Evolution of Treatment Paradigm for AMD: Evaluating the Data from Clinical and Real-life Experience
  • Discuss the place of q12w dosing strategy in current treatment paradigms for AMD
  • Analyze emerging data indicating that every eye is an anti-VEGF responder if diagnosed early and treated
  • Discuss the place of new and emerging treatment strategies and paradigms for nAMD
MODULE FOUR: Treatment Choices for Retinal Vein Occlusion (RVO)
  • Discuss clinical data with anti-VEGF, steroid, and laser therapies and evolving injections paradigms for anti-VEGF
  • Identify cases when steroid or PRP can be used in the first line management of RVO
  • Apply AAO recent Preferred Practice Patterns in the management of patients with RVO
These activities are jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with The American Macular Degeneration Foundation.

ACKNOWLEDGEMENT

These activities are supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

TARGET AUDIENCE

The educational design of these activities addresses the needs of US-based retinal specialists and ophthalmologists who deliver anti-VEGF therapy for patients with diabetic retinopathy (DR), diabetic macular edema (DME), neovascular age-related macular degeneration (nAMD), and retinal vein occlusion (RVO).

STATEMENT OF NEED/PROGRAM OVERVIEW

While the COVID-19 pandemic has dramatically changed health care delivery in the US, patients with vision diseases in need of intravitreal anti-VEGF therapy must adhere to their treatment schedules or risk vision deterioration or loss. This includes patients with DR, DME, nAMD, and RVO. As therapies for these disorders continue to make incremental improvements to minimize treatment burden and improve outcomes, clinicians who provide anti-VEGF therapy need to be kept up to date with the latest data and best practices.

MODULE ONE: Anti-VEGF Injections in the Era of COVID-19: Implications for Patients

Activity Overview

“Anti-VEGF Injections in the Era of COVID-19: Implications for Patients,” will discuss the provision of care during the pandemic and share strategies to reduce risk of transmission between patients, clinicians, and staff.

Date of Release/Expiration

This activity was released on November 17, 2020 and is valid for 6 months. Requests for credit must be made no later than May 17, 2021.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Estimated Time to Complete

This activity should take approximately 30 minutes to complete.

MODULE TWO: Management of the Diabetic Retinopathy: What is New?

Activity Overview

“Management of the Diabetic Retinopathy: What is New?,” the expert panelists will review the most recent data from studies lead by DRCR Retina Network with anti-VEGF therapies and the impacts on management and best practices in the care of DR and DME.

Date of Release/Expiration

This activity was released on November 17, 2020 and is valid for 6 months. Requests for credit must be made no later than May 17, 2021.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Estimated Time to Complete

This activity should take approximately 45 minutes to complete.

MODULE THREE: Evolution of Treatment Paradigm for AMD: Evaluating the Data from Clinical and Real-life Experience

Activity Overview

“Evolution of the Treatment Paradigm for AMD: Evaluating the Data from Clinical and Real-life Experience,” will look at progress with the use of modified dosing regimens and new agents to maximizing visual outcomes in AMD.

Date of Release/Expiration

This activity was released on November 17, 2020 and is valid for 6 months. Requests for credit must be made no later than May 17, 2021.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Estimated Time to Complete

This activity should take approximately 30 minutes to complete.

MODULE FOUR: Treatment Choices for Retinal Vein Occlusion (RVO)

Activity Overview

“Treatment Choices for Retinal Vein Occlusion (RVO),” will explore the latest guidance on selecting and ordering treatments for RVOs.

Date of Release/Expiration

This activity was released on November 17, 2020 and is valid for 6 months. Requests for credit must be made no later than May 17, 2021.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Estimated Time to Complete

This activity should take approximately 30 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for each activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for any of these educational activities.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Jeffrey S. Heier, MD
Co-President & Medical Director
Director, Retina Service
Director, Retina Research
Ophthalmic Consultants of Boston
Consultant/Independent Contractor: 4DMT, Adverum, Aerie, Aerpio, Aldeyra, Allegro, Alzheon, Apellis, Aprea, Asclepix, Aviceda, Beaver-Visitec, DTx, Eloxx, Galimedix, Genentech, Graybug, Gyroscope, iRenix, Iveric, jCyte, Kala, Kanghong, NGM, Notal Vision, Novartis, Ocular Therapeutix, Oxurion, Palatin, Regeneron, Regenxbio, Santen, Stealth, Thea, Vinci, Voyant
Grant/Research Support: Aerpio, Aldeyra, Apellis, Bayer, Genentech, Graybug, Gyroscope, Hemera, Iveric, Janssen R&D, jCyte, Kanghong, Novartis, Regeneron, Regenxbio, Stealth
Stock Shareholder: Adverum, Aldeyra, Allegro, Aviceda, jCyte, Ocular Therapeutix
Charles C. Wykoff, MD, PhD
Physician
Retina Consultants of America
Retina Consultants of Houston
Houston Methodist Hospital & Blanton Eye Institute
Consultant/Independent Contractor: Acucela, Adverum, Alcon, Alimera Sciences, Allergan, Apellis, Arctic Vision, Bausch + Lomb, Bayer, Bionic Vision Technologies, Chengdu Kanghong Biotechnologies (KHB), Clearside Biomedical, DORC, Genentech, Gyroscope, IVERIC Bio, Kodiak Sciences, Merck, NGM Biopharmaceuticals, Novartis, ONL Therapeutics, Opthea, Oxurion, Palatin, Polyphotonix, Recens Medical, Regeneron, RegenXBio, Roche, Takeda, Thea Open Innovation, Verana Health
Speaker’s Bureau: Regeneron
Matthew Levine
Grants, Advocacy and Partnerships Director
American Macular Degeneration Foundation
Nothing to disclose


The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner or Manager Reported Financial Relationship
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Jaimee Harris-Gold Nothing to disclose
Carole Drexel Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.